{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:48:31Z","timestamp":1754261311383,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T00:00:00Z","timestamp":1490832000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40292-017-0198-z","type":"journal-article","created":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T23:39:53Z","timestamp":1490830793000},"page":"127-132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Use of Antihypertensive Drugs in Neoplastic Patients"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1253-0186","authenticated-orcid":false,"given":"Damiano","family":"Rizzoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"De Ciuceis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enzo","family":"Porteri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Agabiti-Rosei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Agabiti-Rosei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,30]]},"reference":[{"key":"198_CR1","doi-asserted-by":"crossref","unstructured":"Svilaas T, Lefrandt JD, Gietema JA, Kamphuisen PW. Long-term arterial complications of chemotherapy in patients with cancer. Thromb Res. 2016;140S1:S109\u201318.","DOI":"10.1016\/S0049-3848(16)30109-8"},{"key":"198_CR2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cjca.2015.12.023","volume":"32","author":"AC Cameron","year":"2016","unstructured":"Cameron AC, Touyz RM, Lang NN. Vascular complications of cancer chemotherapy. Can J Cardiol. 2016;32:852\u201362.","journal-title":"Can J Cardiol"},{"key":"198_CR3","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ajh.2010.25","volume":"23","author":"V Ranpura","year":"2010","unstructured":"Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens. 2010;23:460\u20138.","journal-title":"Am J Hypertens"},{"key":"198_CR4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jama.2011.51","volume":"305","author":"V Ranpura","year":"2011","unstructured":"Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 2011;305:487\u201394.","journal-title":"JAMA"},{"issue":"7","key":"198_CR5","doi-asserted-by":"crossref","first-page":"e101145","DOI":"10.1371\/journal.pone.0101145","volume":"9","author":"LI Faruque","year":"2014","unstructured":"Faruque LI, Lin M, Battistella M, Wiebe N, Reiman T, Hemmelgarn B, Thomas C, Tonelli M. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS One. 2014;9(7):e101145.","journal-title":"PLoS One"},{"key":"198_CR6","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1016\/j.ijcard.2013.01.052","volume":"167","author":"E Conti","year":"2013","unstructured":"Conti E, Romiti A, Musumeci MB, Passerini J, Zezza L, Mastromarino V, D\u2019Antonio C, Marchetti P, Paneni F, Autore C, Volpe M. Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors. Int J Cardiol. 2013;167:2421\u20139.","journal-title":"Int J Cardiol"},{"key":"198_CR7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11523-011-0204-7","volume":"6","author":"G des Guetz","year":"2011","unstructured":"des Guetz G, Uzzan B, Chouahnia K, Mor\u00e8re JF. Cardiovascular toxicity of anti-angiogenic drugs. Target Oncol. 2011;6:197\u2013202.","journal-title":"Target Oncol."},{"key":"198_CR8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12170-013-0309-x","volume":"7","author":"D Rizzoni","year":"2013","unstructured":"Rizzoni D, Paini A, Salvetti M, Rossini C, De Ciuceis C, Agabiti-Rosei C, Muiesan ML. Inhibitors of angiogenesis and blood pressure. Curr Cardiovasc Risk Rep. 2013;7:244\u20137.","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"198_CR9","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1097\/HJH.0000000000000662","volume":"33","author":"AM Thijs","year":"2015","unstructured":"Thijs AM, van Herpen CM, Verweij V, Pertijs J, van den Broek PH, van der Graaf WT, Rongen GA. Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension. J Hypertens. 2015;33:2075\u201382.","journal-title":"J Hypertens"},{"key":"198_CR10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","volume":"121","author":"OP Hamnvik","year":"2015","unstructured":"Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, Kaymakcalan MD, Williams JS. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121:311\u20139.","journal-title":"Cancer"},{"key":"198_CR11","doi-asserted-by":"crossref","unstructured":"Agabiti Rosei E, Rizzoni D. The effects of hypertension on the structure of human resistance arteries. In: Lip GYH, Hall JE, editors. Comprehensive hypertension, chapter 47. Amsterdam: Mosby Elsevier; 2007. p. 579\u201390.","DOI":"10.1016\/B978-0-323-03961-1.50050-7"},{"key":"198_CR12","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/CIRCULATIONAHA.107.763730","volume":"118","author":"BI Levy","year":"2008","unstructured":"Levy BI, Schiffrin EL, Mourad JJ, Agostini D, Vicaut E, Safar ME, Struijker-Boudier HA. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation. 2008;118:968\u201376.","journal-title":"Circulation"},{"key":"198_CR13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/HYPERTENSIONAHA.112.196774","volume":"60","author":"N Jesus-Gonzalez de","year":"2012","unstructured":"de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD. Management of antiangiogenic therapy-induced hypertension. Hypertension. 2012;60:607\u201315.","journal-title":"Hypertension"},{"key":"198_CR14","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/annonc\/mdm550","volume":"19","author":"JJ Mourad","year":"2008","unstructured":"Mourad JJ, Des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19:927\u201334.","journal-title":"Ann Oncol"},{"key":"198_CR15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","volume":"23","author":"SM Bair","year":"2013","unstructured":"Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trend Cardiovasc Med. 2013;23:104\u201313.","journal-title":"Trend Cardiovasc Med"},{"key":"198_CR16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/HYPERTENSIONAHA.116.07618","volume":"68","author":"AH Meiracker Van den","year":"2016","unstructured":"Van den Meiracker AH, Danser J. Mechanisms of hypertension and renal injury during vascular endothelial growth factor signaling inhibition. Hypertension. 2016;68:17\u201323.","journal-title":"Hypertension"},{"key":"198_CR17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ahj.2011.10.018","volume":"163","author":"RM Steingart","year":"2012","unstructured":"Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, Leier CV, Liu G, Lenihan D, Lindenfeld J, Maitland ML, Remick SC, Tang WH. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 2012;163:156\u201363.","journal-title":"Am Heart J."},{"issue":"37","key":"198_CR18","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"2016","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Authors\/Task Force Members, ESC Committee for Practice Guidelines (CPG). ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;2016(37):2768\u2013801.","journal-title":"Eur Heart J"},{"key":"198_CR19","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2174\/0929867323666151221150052","volume":"23","author":"N Divac","year":"2016","unstructured":"Divac N, Naumovi\u0107 R, Stojanovi\u0107 R, Prostran M. The role of immunosuppressive medications in the pathogenesis of hypertension and efficacy and safety of antihypertensive agents in kidney transplant recipients. Curr Med Chem. 2016;23:1941\u201352.","journal-title":"Curr Med Chem"},{"issue":"31","key":"198_CR20","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"2013","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Red\u00f3n J, Zanchetti A, B\u00f6hm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Members Task Force. ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;2013(31):1281\u2013357.","journal-title":"J Hypertens"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40292-017-0198-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-017-0198-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-017-0198-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T06:31:59Z","timestamp":1568961119000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40292-017-0198-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,30]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["198"],"URL":"https:\/\/doi.org\/10.1007\/s40292-017-0198-z","relation":{},"ISSN":["1120-9879","1179-1985"],"issn-type":[{"type":"print","value":"1120-9879"},{"type":"electronic","value":"1179-1985"}],"subject":[],"published":{"date-parts":[[2017,3,30]]}}}